| [1] |
STONE NJ, ROBINSON JG, LICHTENSTEIN AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association task force on practice guidelines[J]. J Am Coll Cardiol, 2014, 63(25 Pt B): 2889-2934.
|
| [2] |
PASTORI D, POLIMENI L, BARATTA F, et al. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease[J]. Dig Liver Dis, 2015, 47(1): 4-11. DOI: 10.1016/j.dld.2014.07.170 |
| [3] |
TSOCHATZIS EA, BOSCH J. Statins in cirrhosis-Ready for prime time[J]. Hepatology, 2017, 66(3): 697-699. DOI: 10.1002/hep.29277 |
| [4] |
GOLDSTEIN JL, BROWN MS. A century of cholesterol and coronaries: From plaques to genes to statins[J]. Cell, 2015, 161(1): 161-172. DOI: 10.1016/j.cell.2015.01.036 |
| [5] |
VARGAS JI, ARRESE M, SHAH VH, et al. Use of statins in patients with chronic liver disease and cirrhosis: Current views and prospects[J]. Curr Gastroenterol Rep, 2017, 19(9): 43. DOI: 10.1007/s11894-017-0584-7 |
| [6] |
DOUMAS M, IMPRIALOS K, DIMAKOPOULOU A, et al. The role of statins in the management of nonalcoholic fatty liver disease[J]. Curr Pharm Des, 2018, 24(38): 4587-4592.
|
| [7] |
ATHYROS VG, BOUTARI C, STAVROPOULOS K, et al. Statins: An under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk[J]. Curr Vasc Pharmacol, 2018, 16(3): 246-253. DOI: 10.2174/1570161115666170621082910 |
| [8] |
CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67(1): 328-357. DOI: 10.1002/hep.29367 |
| [9] |
TREBICKA J, HENNENBERG M, ODENTHAL M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells[J]. J Hepatol, 2010, 53(4): 702-712. DOI: 10.1016/j.jhep.2010.04.025 |
| [10] |
MARRONE G, RUSSO L, ROSADO E, et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins[J]. J Hepatol, 2013, 58(1): 98-103.
|
| [11] |
KUMAR S, GRACE ND, QAMAR AA. Statin use in patients with cirrhosis: A retrospective cohort study[J]. Dig Dis Sci, 2014, 59(8): 1958-1965. DOI: 10.1007/s10620-014-3179-2 |
| [12] |
CHANG FM, WANG YP, LANG HC, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study[J]. Hepatology, 2017, 66(3): 896-907. DOI: 10.1002/hep.29172 |
| [13] |
MOHANTY A, TATE JP, GARCIA-TSAO G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis[J]. Gastroenterology, 2016, 150(2): 430-440. DOI: 10.1053/j.gastro.2015.10.007 |
| [14] |
DONGIOVANNI P, PETTA S, MANNISTO V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals[J]. J Hepatol, 2015, 63(3): 705-712. DOI: 10.1016/j.jhep.2015.05.006 |
| [15] |
NASCIMBENI F, ARON-WISNEWSKY J, PAIS R, et al. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease[J]. BMJ Open Gastroenterol, 2016, 3(1): e000075. DOI: 10.1136/bmjgast-2015-000075 |
| [16] |
TREBICKA J, SCHIERWAGEN R. Statins, Rho GTPases and KLF2: New mechanistic insight into liver fibrosis and portal hypertension[J]. Gut, 2015, 64(9): 1349-1350. DOI: 10.1136/gutjnl-2014-308800 |
| [17] |
ABRALDES JG, ALBILLOS A, BAÑARES R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: A randomized controlled trial[J]. Gastroenterology, 2009, 136(5): 1651-1658. DOI: 10.1053/j.gastro.2009.01.043 |
| [18] |
POLLO-FLORES P, SOLDAN M, SANTOS UC, et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial[J]. Dig Liver Dis, 2015, 47(11): 957-963. DOI: 10.1016/j.dld.2015.07.156 |
| [19] |
ABRALDES JG, VILLANUEVA C, ARACIL C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis[J]. Gastroenterology, 2016, 150(5): 1160-1170. DOI: 10.1053/j.gastro.2016.01.004 |
| [20] |
FUJIWARA D, TSUBAKI M, TAKEDA T, et al. Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells[J]. Tumour Biol, 2017, 39(10): 1010428317734947.
|
| [21] |
YOKOHAMA K, FUKUNISHI S, Ⅱ M, et al. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice[J]. Int J Mol Med, 2016, 38(5): 1499-1506. DOI: 10.3892/ijmm.2016.2766 |
| [22] |
SINGH S, SINGH PP, SINGH AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis[J]. Gastroenterology, 2013, 144(2): 323-332. DOI: 10.1053/j.gastro.2012.10.005 |
| [23] |
SHI M, ZHENG H, NIE B, et al. Statin use and risk of liver cancer: An update meta-analysis[J]. BMJ Open, 2014, 4(9): e005399. DOI: 10.1136/bmjopen-2014-005399 |
| [24] |
KIM G, JANG SY, NAM CM, et al. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study[J]. J Hepatol, 2018, 68(3): 476-484. DOI: 10.1016/j.jhep.2017.10.018 |
| [25] |
NISHIO T, TAURA K, NAKAMURA N, et al. Impact of statin use on the prognosis of patients with hepatocellular carcinoma undergoing liver resection: A subgroup analysis of patients without chronic hepatitis viral infection[J]. Surgery, 2018, 163(2): 264-269. DOI: 10.1016/j.surg.2017.09.026 |
| [26] |
LAW M, RUDNICKA AR. Statin safety: A systematic review[J]. Am J Cardiol, 2006, 97(8A): 52C-60C.
|
| [27] |
PFEFFER MA, KEECH A, SACKS FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project[J]. Circulation, 2002, 105(20): 2341-2346. DOI: 10.1161/01.CIR.0000017634.00171.24 |
| [28] |
BISHNU S, AHAMMED SM, SARKAR A, et al. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: A proof-of-concept study[J]. Eur J Gastroenterol Hepatol, 2018, 30(1): 54-59. DOI: 10.1097/MEG.0000000000001006 |
DownLoad: